KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Short-Term Debt issuances (2017 - 2023)

Teva Pharmaceutical Industries (TEVA) has disclosed Short-Term Debt issuances for 5 consecutive years, with $200.0 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Short-Term Debt issuances fell 37.3% year-over-year to $200.0 million, compared with a TTM value of $200.0 million through Dec 2023, down 61.46%, and an annual FY2023 reading of $700.0 million, changed N/A over the prior year.
  • Short-Term Debt issuances was $200.0 million for Q4 2021 at Teva Pharmaceutical Industries, down from $319.0 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $404.0 million in Q4 2019 and bottomed at -$1.4 billion in Q1 2017.
  • Average Short-Term Debt issuances over 5 years is -$33.1 million, with a median of $48.5 million recorded in 2018.
  • The sharpest move saw Short-Term Debt issuances skyrocketed 9900.0% in 2019, then tumbled 37.3% in 2021.
  • Year by year, Short-Term Debt issuances stood at -$1.4 billion in 2017, then soared by 119.41% to $262.0 million in 2018, then surged by 54.2% to $404.0 million in 2019, then fell by 21.04% to $319.0 million in 2020, then tumbled by 37.3% to $200.0 million in 2021.
  • Business Quant data shows Short-Term Debt issuances for TEVA at $200.0 million in Q4 2021, $319.0 million in Q4 2020, and $404.0 million in Q4 2019.